Replies to post #165803 on Biotech Values

[jq1234]

Dificid/Dificlir fidaxomicin as first line treatment of CDI in real world 28-day all-cause mortality data presented at FIS 2014:

Data collected from a total of 107 patients treated first-line with fidaxomicin during the 12 month evaluation period were compared with those from a retrospective cohort treated with standard of care (vancomycin or metronidazole) during the previous 12 month period.[2] In the group treated with fidaxomicin first line, in addition to the significant reduction in relative recurrence, there was also a lower 28-day all-cause mortality compared to older treatments (7.6% vs. 23.3% respectively).[2]

http://www.prnewswire.co.uk/news-releases/dificlir-fidaxomicin-proven-to-be-both-clinically-and-cost-effective-compared-to-standard-of-care-in-real-world-patients-with-clostridium-difficile-infection-283902041.html